Loading…
Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration
Objective To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. Animals studied Five healthy Thoroughbred horses. Procedures Voriconazole was administra...
Saved in:
Published in: | Veterinary ophthalmology 2020-07, Vol.23 (4), p.640-647 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63 |
---|---|
cites | cdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63 |
container_end_page | 647 |
container_issue | 4 |
container_start_page | 640 |
container_title | Veterinary ophthalmology |
container_volume | 23 |
creator | Tamura, Norihisa Okano, Atsushi Kuroda, Taisuke Niwa, Hidekazu Kusano, Kanichi Matsuda, Yoshikazu Fukuda, Kentaro Mita, Hiroshi Nagata, Shunichi |
description | Objective
To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis.
Animals studied
Five healthy Thoroughbred horses.
Procedures
Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle.
Results
The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was >100 and 25.7, respectively.
Conclusions
This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis. |
doi_str_mv | 10.1111/vop.12764 |
format | article |
fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>VOP12764</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</originalsourceid><addsrcrecordid>eNp1kU9PHCEYh0lTU63toV_AcO1hFYY_M3MxaYy2TUz0oL2Sd4BRlIEtzO5mPPUjePTz9ZOU7erGHsoFAs_7_Eh-CH2i5JCWdbSM80Na1ZK_QXuUSzYTVcXfbs9U7qL3Od8RQpgg9Tu0yyrWMFHJPfR0PTrvxgnHHucpj3ZwGi9jcjoGeIjeYhew_blwweJ7m2CMw6Rjdhl3kK3BMeD5LaQBdLwvzOj071-PLzdmCrD2QQA_rWdKyGgh4d4vnMF99D6uXLjBMYHHYAYXXB5LiIvhA9rpwWf78XnfR9dnp1cn32bnF1-_n3w5n2lOBZ-1tjVghBG95ZpxzQlQxqmWnSCVbKBhUElqQOi-Y9q2NesawimITtSkAcn20fHGO190gzXahvIBr-bJDZAmFcGpf1-Cu1U3calq3sq2YkXweSPQKeacbL-dpUSt61GlHvW3nsIevA7bki99FOBoA6yct9P_TerHxeVG-QfPKaH_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tamura, Norihisa ; Okano, Atsushi ; Kuroda, Taisuke ; Niwa, Hidekazu ; Kusano, Kanichi ; Matsuda, Yoshikazu ; Fukuda, Kentaro ; Mita, Hiroshi ; Nagata, Shunichi</creator><creatorcontrib>Tamura, Norihisa ; Okano, Atsushi ; Kuroda, Taisuke ; Niwa, Hidekazu ; Kusano, Kanichi ; Matsuda, Yoshikazu ; Fukuda, Kentaro ; Mita, Hiroshi ; Nagata, Shunichi</creatorcontrib><description>Objective
To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis.
Animals studied
Five healthy Thoroughbred horses.
Procedures
Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle.
Results
The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was >100 and 25.7, respectively.
Conclusions
This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.</description><identifier>ISSN: 1463-5216</identifier><identifier>EISSN: 1463-5224</identifier><identifier>DOI: 10.1111/vop.12764</identifier><identifier>PMID: 32383526</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Administration, Oral ; Animals ; Antifungal Agents - administration & dosage ; Antifungal Agents - pharmacokinetics ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; Area Under Curve ; Aspergillus ; Aspergillus - drug effects ; Eye Infections, Fungal - drug therapy ; Eye Infections, Fungal - veterinary ; Female ; horse ; Horse Diseases - blood ; Horse Diseases - drug therapy ; Horses - metabolism ; keratomycosis ; Male ; Microbial Sensitivity Tests ; Original ; pharmacodynamics ; pharmacokinetics ; tear fluid ; Tears - metabolism ; Voriconazole - administration & dosage ; Voriconazole - pharmacokinetics ; Voriconazole - pharmacology ; Voriconazole - therapeutic use</subject><ispartof>Veterinary ophthalmology, 2020-07, Vol.23 (4), p.640-647</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC on behalf of American College of Veterinary Ophthalmologists</rights><rights>2020 The Authors. Veterinary Ophthalmology published by Wiley Periodicals LLC on behalf of American College of Veterinary Ophthalmologists.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</citedby><cites>FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</cites><orcidid>0000-0002-9138-6839</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32383526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamura, Norihisa</creatorcontrib><creatorcontrib>Okano, Atsushi</creatorcontrib><creatorcontrib>Kuroda, Taisuke</creatorcontrib><creatorcontrib>Niwa, Hidekazu</creatorcontrib><creatorcontrib>Kusano, Kanichi</creatorcontrib><creatorcontrib>Matsuda, Yoshikazu</creatorcontrib><creatorcontrib>Fukuda, Kentaro</creatorcontrib><creatorcontrib>Mita, Hiroshi</creatorcontrib><creatorcontrib>Nagata, Shunichi</creatorcontrib><title>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</title><title>Veterinary ophthalmology</title><addtitle>Vet Ophthalmol</addtitle><description>Objective
To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis.
Animals studied
Five healthy Thoroughbred horses.
Procedures
Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle.
Results
The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was >100 and 25.7, respectively.
Conclusions
This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antifungal Agents - administration & dosage</subject><subject>Antifungal Agents - pharmacokinetics</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Aspergillus</subject><subject>Aspergillus - drug effects</subject><subject>Eye Infections, Fungal - drug therapy</subject><subject>Eye Infections, Fungal - veterinary</subject><subject>Female</subject><subject>horse</subject><subject>Horse Diseases - blood</subject><subject>Horse Diseases - drug therapy</subject><subject>Horses - metabolism</subject><subject>keratomycosis</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Original</subject><subject>pharmacodynamics</subject><subject>pharmacokinetics</subject><subject>tear fluid</subject><subject>Tears - metabolism</subject><subject>Voriconazole - administration & dosage</subject><subject>Voriconazole - pharmacokinetics</subject><subject>Voriconazole - pharmacology</subject><subject>Voriconazole - therapeutic use</subject><issn>1463-5216</issn><issn>1463-5224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kU9PHCEYh0lTU63toV_AcO1hFYY_M3MxaYy2TUz0oL2Sd4BRlIEtzO5mPPUjePTz9ZOU7erGHsoFAs_7_Eh-CH2i5JCWdbSM80Na1ZK_QXuUSzYTVcXfbs9U7qL3Od8RQpgg9Tu0yyrWMFHJPfR0PTrvxgnHHucpj3ZwGi9jcjoGeIjeYhew_blwweJ7m2CMw6Rjdhl3kK3BMeD5LaQBdLwvzOj071-PLzdmCrD2QQA_rWdKyGgh4d4vnMF99D6uXLjBMYHHYAYXXB5LiIvhA9rpwWf78XnfR9dnp1cn32bnF1-_n3w5n2lOBZ-1tjVghBG95ZpxzQlQxqmWnSCVbKBhUElqQOi-Y9q2NesawimITtSkAcn20fHGO190gzXahvIBr-bJDZAmFcGpf1-Cu1U3calq3sq2YkXweSPQKeacbL-dpUSt61GlHvW3nsIevA7bki99FOBoA6yct9P_TerHxeVG-QfPKaH_</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Tamura, Norihisa</creator><creator>Okano, Atsushi</creator><creator>Kuroda, Taisuke</creator><creator>Niwa, Hidekazu</creator><creator>Kusano, Kanichi</creator><creator>Matsuda, Yoshikazu</creator><creator>Fukuda, Kentaro</creator><creator>Mita, Hiroshi</creator><creator>Nagata, Shunichi</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9138-6839</orcidid></search><sort><creationdate>202007</creationdate><title>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</title><author>Tamura, Norihisa ; Okano, Atsushi ; Kuroda, Taisuke ; Niwa, Hidekazu ; Kusano, Kanichi ; Matsuda, Yoshikazu ; Fukuda, Kentaro ; Mita, Hiroshi ; Nagata, Shunichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antifungal Agents - administration & dosage</topic><topic>Antifungal Agents - pharmacokinetics</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Aspergillus</topic><topic>Aspergillus - drug effects</topic><topic>Eye Infections, Fungal - drug therapy</topic><topic>Eye Infections, Fungal - veterinary</topic><topic>Female</topic><topic>horse</topic><topic>Horse Diseases - blood</topic><topic>Horse Diseases - drug therapy</topic><topic>Horses - metabolism</topic><topic>keratomycosis</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Original</topic><topic>pharmacodynamics</topic><topic>pharmacokinetics</topic><topic>tear fluid</topic><topic>Tears - metabolism</topic><topic>Voriconazole - administration & dosage</topic><topic>Voriconazole - pharmacokinetics</topic><topic>Voriconazole - pharmacology</topic><topic>Voriconazole - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamura, Norihisa</creatorcontrib><creatorcontrib>Okano, Atsushi</creatorcontrib><creatorcontrib>Kuroda, Taisuke</creatorcontrib><creatorcontrib>Niwa, Hidekazu</creatorcontrib><creatorcontrib>Kusano, Kanichi</creatorcontrib><creatorcontrib>Matsuda, Yoshikazu</creatorcontrib><creatorcontrib>Fukuda, Kentaro</creatorcontrib><creatorcontrib>Mita, Hiroshi</creatorcontrib><creatorcontrib>Nagata, Shunichi</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamura, Norihisa</au><au>Okano, Atsushi</au><au>Kuroda, Taisuke</au><au>Niwa, Hidekazu</au><au>Kusano, Kanichi</au><au>Matsuda, Yoshikazu</au><au>Fukuda, Kentaro</au><au>Mita, Hiroshi</au><au>Nagata, Shunichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</atitle><jtitle>Veterinary ophthalmology</jtitle><addtitle>Vet Ophthalmol</addtitle><date>2020-07</date><risdate>2020</risdate><volume>23</volume><issue>4</issue><spage>640</spage><epage>647</epage><pages>640-647</pages><issn>1463-5216</issn><eissn>1463-5224</eissn><abstract>Objective
To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis.
Animals studied
Five healthy Thoroughbred horses.
Procedures
Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle.
Results
The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was >100 and 25.7, respectively.
Conclusions
This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>32383526</pmid><doi>10.1111/vop.12764</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9138-6839</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1463-5216 |
ispartof | Veterinary ophthalmology, 2020-07, Vol.23 (4), p.640-647 |
issn | 1463-5216 1463-5224 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496923 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Administration, Oral Animals Antifungal Agents - administration & dosage Antifungal Agents - pharmacokinetics Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Area Under Curve Aspergillus Aspergillus - drug effects Eye Infections, Fungal - drug therapy Eye Infections, Fungal - veterinary Female horse Horse Diseases - blood Horse Diseases - drug therapy Horses - metabolism keratomycosis Male Microbial Sensitivity Tests Original pharmacodynamics pharmacokinetics tear fluid Tears - metabolism Voriconazole - administration & dosage Voriconazole - pharmacokinetics Voriconazole - pharmacology Voriconazole - therapeutic use |
title | Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20systemic%20voriconazole%20in%20equine%20keratomycosis%20based%20on%20pharmacokinetic%E2%80%90pharmacodynamic%20analysis%20of%20tear%20fluid%20following%20oral%20administration&rft.jtitle=Veterinary%20ophthalmology&rft.au=Tamura,%20Norihisa&rft.date=2020-07&rft.volume=23&rft.issue=4&rft.spage=640&rft.epage=647&rft.pages=640-647&rft.issn=1463-5216&rft.eissn=1463-5224&rft_id=info:doi/10.1111/vop.12764&rft_dat=%3Cwiley_pubme%3EVOP12764%3C/wiley_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32383526&rfr_iscdi=true |